Triplet Delays Breast Cancer Progression in First-Line Maintenance Setting

(MedPage Today) -- SAN ANTONIO--Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab and pertuzumab (Perjeta) significantly improved progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer...